熱門資訊> 正文
Bausch + Lomb因潜在销售传闻而上涨13%
2024-09-16 23:14
- Bausch + Lomb (NYSE:BLCO) is up ~13% in Monday morning trading following a report that came out Sept. 14 that the eye care company is interested in a sale.
- B+L is said to be interested in potential buyers to appease lenders who have expressed concerns over its planned full separation from Bausch Health (NYSE:BHC), per a report in the Financial Times.
- Although B+L has traded on its own since 2022, Bausch Health still retains an 88% stake.
- A slew of creditors, including Apollo Global Management and Elliott Management, have argued that Bausch Health's plan to exchange its B+L shares for Bausch Health shares could negatively impact Bausch's balance sheet.
- Bausch currently has ~$21B in debt. The stock is up ~5% Monday morning
- If a B+L sale happens, it would likely placate two of Bausch's largest shareholders, funds run by Carl Icahn and John Paulson.
More on Bausch Health, Bausch + Lomb
- Bausch Health Companies (BHC) Q2 2024 Earnings Call Transcript
- Bausch Health Companies Inc. 2024 Q2 - Results - Earnings Call Presentation
- Bausch + Lomb Corporation 2024 Q2 - Results - Earnings Call Presentation
- Biggest stock movers today: AAPL, DJT, INTC, BLCO and more
- Bausch + Lomb reportedly exploring sale to handle Bausch Health spinoff
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
